ResearcherWestern UniversityActive in the last 2 years

Fatemeh Mousavi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0009-5880-3045; OpenAlex author ID A5085530453. Sources: OpenAlex.

Their work

Papers: 3
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 14

Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 3

Mouse Models for Pancreatic Ductal Adenocarcinoma are Affected by the cre-driver Used to Promote KRAS G12D Activation. Co-author DOI 10.1016/j.jcmgh.2024.101428 ↗
EZH2 deletion does not affect acinar regeneration but restricts progression to pancreatic cancer in mice. Co-author DOI 10.1172/jci.insight.173746 ↗
Loss of activating transcription factor 3 prevents KRAS-mediated pancreatic cancer. Co-author DOI 10.1038/s41388-021-01771-z ↗

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Christopher L. Pin · 3 shared papers, 2021–2025 · strength 0.53
Joyce K. Thompson · 1 shared paper, 2025 · strength 0.24
- Paper Mouse Models for Pancreatic Ductal Adenocarcinoma are Affected by the cre-driver Used to Promote KRAS G12D Activation. DOI 10.1016/j.jcmgh.2024.101428 ↗
Timothy L. Frankel · 1 shared paper, 2025 · strength 0.24
- Paper Mouse Models for Pancreatic Ductal Adenocarcinoma are Affected by the cre-driver Used to Promote KRAS G12D Activation. DOI 10.1016/j.jcmgh.2024.101428 ↗
Filip Bednar · 1 shared paper, 2025 · strength 0.24
- Paper Mouse Models for Pancreatic Ductal Adenocarcinoma are Affected by the cre-driver Used to Promote KRAS G12D Activation. DOI 10.1016/j.jcmgh.2024.101428 ↗
Emilie Jaune · 1 shared paper, 2024 · strength 0.17
- Paper EZH2 deletion does not affect acinar regeneration but restricts progression to pancreatic cancer in mice. DOI 10.1172/jci.insight.173746 ↗
Abdessamad El Kaoutari · 1 shared paper, 2024 · strength 0.17
- Paper EZH2 deletion does not affect acinar regeneration but restricts progression to pancreatic cancer in mice. DOI 10.1172/jci.insight.173746 ↗
Raul A. Urrutia · 1 shared paper, 2024 · strength 0.17
- Paper EZH2 deletion does not affect acinar regeneration but restricts progression to pancreatic cancer in mice. DOI 10.1172/jci.insight.173746 ↗
Gwen Alyce Lomberk · 1 shared paper, 2024 · strength 0.17
- Paper EZH2 deletion does not affect acinar regeneration but restricts progression to pancreatic cancer in mice. DOI 10.1172/jci.insight.173746 ↗
Nelson Dusetti · 1 shared paper, 2024 · strength 0.17
- Paper EZH2 deletion does not affect acinar regeneration but restricts progression to pancreatic cancer in mice. DOI 10.1172/jci.insight.173746 ↗
Nina G. Steele · 1 shared paper, 2021 · strength 0.12
- Paper Loss of activating transcription factor 3 prevents KRAS-mediated pancreatic cancer. DOI 10.1038/s41388-021-01771-z ↗
María Teresa Borrello · 1 shared paper, 2021 · strength 0.12
- Paper Loss of activating transcription factor 3 prevents KRAS-mediated pancreatic cancer. DOI 10.1038/s41388-021-01771-z ↗
Nawab Azizi · 1 shared paper, 2021 · strength 0.12
- Paper Loss of activating transcription factor 3 prevents KRAS-mediated pancreatic cancer. DOI 10.1038/s41388-021-01771-z ↗
Marina Pasca di Magliano · 1 shared paper, 2021 · strength 0.12
- Paper Loss of activating transcription factor 3 prevents KRAS-mediated pancreatic cancer. DOI 10.1038/s41388-021-01771-z ↗
Jiaqi Shi · 1 shared paper, 2021 · strength 0.12
- Paper Loss of activating transcription factor 3 prevents KRAS-mediated pancreatic cancer. DOI 10.1038/s41388-021-01771-z ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.